US Patent

US8168620 — Combination of azelastine and steroids

Formulation · Assigned to Cipla Ltd · Expires 2026-02-24 · 0y expired

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical product or formulation that combines azelastine or a derivative with a steroid, suitable for nasal or ocular administration.

USPTO Abstract

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

Drugs covered by this patent

Patent Metadata

Patent number
US8168620
Jurisdiction
US
Classification
Formulation
Expires
2026-02-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Cipla Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.